Barclays’s Roivant Sciences ROIV Stock Holding History

Barclays’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,100	Closed	-$16.6K	–	5610
2025 Q3	$16.6K	Buy	+1,100	New	+$13.6K	﹤0.01%	4967

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's ROIV Position: Q1 2026 in Review

Barclays increased its Roivant Sciences (ROIV) stake by 69% in Q1 2026, buying an estimated $14.8M and bringing the position to 1,415,848 shares worth $39.2M. The position accounts for 0.01% of the portfolio, ranked #812.

Barclays first reported a position in ROIV in Q1 2022 and has held it in 17 quarters since. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Barclays held 1,415,848 shares of Roivant Sciences worth $39.2M as of Q1 2026.
Barclays bought 576,569 Roivant Sciences shares in Q1 2026, an estimated $14.8M.
Roivant Sciences made up 0.01% of Barclays's portfolio in Q1 2026, its #812 holding.
Barclays first reported a position in Roivant Sciences in Q1 2022 and has held it in 17 quarters since.
440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.